Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Complex for preventing or weakening pulmonary fibrosis, preparation prepared from complex and application of complex

A technology of pulmonary fibrosis and compound, which is applied in the field of compound and its preparation for preventing or weakening pulmonary fibrosis, to achieve the effects of reducing occurrence and development, stabilizing drug release, and improving bioavailability

Active Publication Date: 2016-11-23
THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the prior art, there is no report on the combination of metformin-based biguanides and EGFR-TKI or ALK-TKI such as gefitinib for the prevention or attenuation of pulmonary fibrosis for the treatment of interstitial pneumonia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Complex for preventing or weakening pulmonary fibrosis, preparation prepared from complex and application of complex
  • Complex for preventing or weakening pulmonary fibrosis, preparation prepared from complex and application of complex
  • Complex for preventing or weakening pulmonary fibrosis, preparation prepared from complex and application of complex

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 A Compound for Preventing or Attenuating Pulmonary Fibrosis

[0032] The complex includes 3 parts by weight of metformin and 2 parts by weight of gefitinib.

Embodiment 2

[0033] Example 2 A kind of bilayer tablet

[0034] Chip:

[0035]

[0036] Immediate release layer:

[0037]

Embodiment 3

[0038] Example 3 A kind of bilayer tablet

[0039] Chip:

[0040]

[0041] Immediate release layer:

[0042]

[0043] Animal experiment

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a complex of biguanide and EGFR (Epidermal growth factor receptor)-TKI (Tyrosine kinase inhibitor) or ALK (anaplastic lymphoma kinase)-TKI and application of the complex. The complex can be used for preventing or relieving interstitial pneumonia and particularly the interstitial pneumonia caused by EGFR-TKI or ALK-TKI during treatment of NSCLC (Non-Small Cell Lung Cancer). The complex can prevent complications caused by EGFR-TKI or ALK-TKI during treatment of NSCLC, thereby effectively improving the treatment effect of EGFR-TKI or ALK-TKI and reducing the occurrence and development of complications of a patient.

Description

technical field [0001] The invention belongs to the field of medical application, in particular to a compound for preventing or weakening pulmonary fibrosis, its preparation and application. Background technique [0002] Lung cancer is the malignant tumor with the highest morbidity and mortality worldwide; non-small cell lung cancer (Non Small Cell Lung Cancer, NSCLC) accounts for 80% to 85% of all lung cancer cases. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) play an important role in the development of NSCLC. Targeted drugs represented by EGFR tyrosine kinase inhibitor (TKI) and ALK-TKI have achieved remarkable curative effect on certain NSCLC patients, but a serious complication-interstitial pneumonia occurred during TKI treatment; Although its incidence rate is low, once it occurs, it often has a fatal impact on patients. [0003] EGFR-TKI represented by gefitinib (gefitnib, Iressa) is a small-molecule targeted drug approved by many cou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/5377A61P11/00A61K31/155
Inventor 何勇李力
Owner THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com